Tolazoline HCl

Tolazoline hydrochloride is a combination alpha-one and alpha-two antagonist developed to reverse the sedation and analgesia effects of xylazine hydrochloride. Tolazoline hydrochloride was developed and marketed for use in horses by Lloyd Laboratories in the 1990s. It was approved under the trade name Tolazine in 1996. Prior to this tolazoline was available as the human formulation trademarked Priscoline at a concentration of 25 mg/ml from Novartis.